An anticancer pharmaceutical composition

Abstract

The invention relates the anti-cancer drugs. The drugs comprise medicinal findings and DNA duplicate inhibiting agent. The DNA duplicate inhibiting agent, from polymeric (ADP- ribose) polymerization inhibitor and DNA-dependence protease inhibitor, destructs the DNA refinishing function in tumor cell, and reduces the survivability. The medicinal findings comprises degradable absorbing high molecular polymer, and at the course of degrading and absorbing, the findings can release the DNA duplicate inhibiting agent into the tumor parts, reducing the toxicity reaction and keeping effective drug concentration. The anti-cancer drugs also comprise nitrosourea drugs, which can reduce toxicity reaction and improve therapeutic efficacy.

Description

[0001] This application is a divisional application of 200410035923.7. (1) Technical field

[0002] The invention relates to an anticancer drug composition, which belongs to the technical field of drugs. (2) Background technology

[0003] The treatment of solid tumors mainly includes surgery, radiotherapy and chemotherapy. Among the various chemotherapeutic drugs used, nitrosourea anticancer drugs have obvious effects and have been widely used in various malignant tumors. However, further research found that the DNA repair function in many tumor cells increased significantly after the treatment. The latter often leads to enhanced resistance of tumor cells to nitrosourea anticancer drugs, resulting in treatment failure.

[0004] It has recently been found that inactivation or inhibition of intracellular DNA repair proteins can enhance the sensitivity of some tumor cells to chemotherapy (see Dolan et al. ""Cancer Research" 51 pp. 3367-3372 (1991) (Dolan et al., Cancer Res.,...